Fasenra is administered via subcutaneous injection. It can be injected into the thigh, abdomen, or upper arm. The medication is available in two forms:

• Prefilled Syringe: For administration by a healthcare professional.
  
  
• Autoinjector (Fasenra Pen): For self-administration by patients or caregivers after proper training.
  
  

Before injection:

• Allow Fasenra to reach room temperature by leaving it out of the refrigerator for about 30 minutes.
  
  
• Inspect the solution for any particles or discoloration. The solution should be clear to opalescent and colorless to slightly yellow.
  
  
• Do not use if the solution is cloudy, discolored, or contains large particles.
  
  

Always follow the specific instructions provided by your healthcare provider or pharmacist.

Fasenra works by targeting the interleukin-5 receptor alpha (IL-5Ra) on the surface of eosinophils. By binding to this receptor, Fasenra:

• Reduces eosinophil levels: Decreases the number of eosinophils in the blood and lungs, leading to reduced inflammation.
  
  
• Enhances eosinophil death: Activates natural killer (NK) cells to induce programmed cell death (apoptosis) of eosinophils through antibody-dependent cell-mediated cytotoxicity (ADCC).
  
  
• Improves asthma control: By lowering eosinophil counts, Fasenra helps alleviate asthma symptoms and reduce the frequency of exacerbations.
  
  

This mechanism of action is particularly beneficial for patients with eosinophilic asthma, where elevated eosinophil levels contribute to airway inflammation and asthma symptoms.

Common Side Effects

• Headache: A common occurrence, usually mild to moderate.
  
  
• Sore Throat: May cause discomfort in the throat area.
  
  
• Fever: Some patients may experience a mild fever after injection.
  
  

Serious Side Effects

• Hypersensitivity Reactions: Including anaphylaxis, angioedema, urticaria, and rash. These reactions can occur within hours or days after administration.
  
  
• Injection Site Reactions: Pain, redness, or swelling at the injection site.
  
  
• Anti-Drug Antibodies: Some patients may develop antibodies against benralizumab, potentially affecting the drug’s efficacy.
  
  

If you experience any of these side effects, contact your healthcare provider immediately.

• Not for Acute Symptoms: Fasenra is not intended to treat acute asthma symptoms or exacerbations. Always have a rescue inhaler available for sudden asthma attacks.
  
  
• Corticosteroid Reduction: Do not abruptly discontinue systemic or inhaled corticosteroids upon starting Fasenra therapy. Gradual reduction should be done under medical supervision to avoid withdrawal symptoms.
  
  
• Hypersensitivity Reactions: Be vigilant for signs of allergic reactions, especially during the first few hours after injection. Seek immediate medical attention if you experience symptoms like difficulty breathing, swelling of the face or throat, or severe rash.
  
  
• Infection Risk: Fasenra may increase the risk of infections. Inform your healthcare provider if you have a history of infections or are currently experiencing an infection.
  
  

Fasenra has no known significant drug interactions. However, always inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements, to ensure safe and effective use.

• Administration Sites: Fasenra can be injected into the thigh, abdomen, or upper arm. The choice of site may depend on whether the injection is administered by a healthcare provider or self-administered.
  
  
• Injection Technique: Proper technique is crucial to ensure effective delivery and minimize discomfort. Training is provided for patients or caregivers who will be administering the injection themselves.
  
  
• Storage: Store Fasenra in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the medication in its original carton to protect it from light.
  
  

Fasenra is a prescription-only medication. It should be prescribed by a healthcare provider experienced in the diagnosis and treatment of severe asthma or EGPA. Before starting treatment, your healthcare provider will assess your medical history, current medications, and the severity of your condition to determine if Fasenra is appropriate for you.

Regular follow-up appointments will be necessary to monitor your response to the medication and adjust the treatment plan as needed.

• What is Fasenra used for?
  It is prescribed for severe eosinophilic asthma in adults and children 12 years and older to help reduce asthma attacks and dependence on oral steroids.

• What is the active ingredient?
  Benralizumab, a monoclonal antibody.

• How does Fasenra work?
  It targets and binds to interleukin-5 receptor alpha (IL-5Rα) on eosinophils, signaling the immune system to destroy these cells — reducing inflammation in the airways.

• Is Fasenra a steroid?
  No, it is a biologic (monoclonal antibody), not a corticosteroid.

• How is Fasenra given?
  As a subcutaneous (under the skin) injection by a healthcare provider or self-administered with an autoinjector.

• What is the usual dosing schedule?

  • Once every 4 weeks for the first 3 doses, then

  • Once every 8 weeks thereafter.

• What are the common side effects?
  Headache, sore throat, fever, and injection site reactions (redness, itching, or pain).

• Are there serious side effects?
  Rare but possible — allergic reactions, anaphylaxis, or immune-related responses.

• Does Fasenra work right away?
  Many patients notice improvement in symptoms within 4–8 weeks, though full benefits may take longer.

• Can Fasenra replace inhalers?
  No — it is used alongside standard asthma treatments (like inhaled corticosteroids and bronchodilators).

• Who should not take Fasenra?
  Anyone with a known allergy to benralizumab or its components.

• Is Fasenra safe for children?
  Approved for children 12 years and older with eosinophilic asthma.

• Is Fasenra safe during pregnancy?
  Use only if clearly needed — safety in pregnancy has not been fully established.

• Can I take Fasenra while breastfeeding?
  Unknown if it passes into breast milk; discuss with your doctor before use.

• Does Fasenra suppress the immune system?
  It specifically targets eosinophils, not general immune suppression, so infection risk is relatively low.

• Can I get vaccines while on Fasenra?
  Yes, but live vaccines should be avoided unless approved by your doctor.

• What conditions besides asthma can Fasenra treat?
  It is also approved for eosinophilic granulomatosis with polyangiitis (EGPA) and being studied for chronic obstructive pulmonary disease (COPD).

• How is Fasenra stored?
  Store in the refrigerator (36°F–46°F / 2°C–8°C); protect from light and do not freeze.

• Is there a generic version available?
  No, Fasenra (benralizumab) is brand only.

• Where can I get Fasenra?
  Available at clinics, hospitals, or through specialty pharmacies with a prescription.